1. Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice
   M. Yu. Fedyanin, 2020, Pelvic Surgery and Oncology CrossRef
2. Surface Immobilization of Anti-VEGF Peptide on SPIONs for Antiangiogenic and Targeted Delivery of Paclitaxel in Non-Small-Cell Lung Carcinoma
   Lindokuhle M. Ngema et al, 2023, ACS Applied Bio Materials CrossRef
3. Use of Doubling Number as an Arithmetic Measure of Plant Cell Growth and Metal-Induced Cell Growth Inhibition
   Mert METİN et al, 2024, Gazi University Journal of Science CrossRef
4. Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review
   Yihui Lei et al, 2023, Frontiers in Oncology CrossRef
5. Further Therapeutic Options in Heavily Pretreated Colorectal Cancer Patients
   Aneta L. Zygulska, 2019, Multidisciplinary Approach for Colorectal Cancer CrossRef
6. Recent Advances in Biological Active Sulfonamide based Hybrid Compounds Part B: Two-Component Sulfonamide Hybrids
   Shakila Ghomashi et al, 2023, Current Medicinal Chemistry CrossRef
7. PD-L1 antibody enhanced β-glucan antitumor effects via blockade of the immune checkpoints in a melanoma model
   Xin Hu et al, 2023, Cancer Immunology, Immunotherapy CrossRef
8. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study
   Yohei Nose et al, 2020, Cancer Chemotherapy and Pharmacology CrossRef
9. Nanoemulsion Applications
   Ayodeji Ojo Oteyola et al, 2022, Handbook of Research on Nanoemulsion Applications in Agriculture, Food, Health, and Biomedical Sciences CrossRef
10. Clinical Phase I Study of TAS102/Irinotecan/Bevacizumab Combination Therapy in Japanese Patients With Unresectable Metastatic Colorectal Cancer (mCRC)
    Tomohiro Adachi et al, 2023, Cureus CrossRef
11. Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer
    Thierry André et al, 2024, Current Treatment Options in Oncology CrossRef
12. Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model
    Shahrokh Abdolahi et al, 2021, Frontiers in Pharmacology CrossRef
13. Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy
    John Fetse et al, 2022, Journal of Medicinal Chemistry CrossRef
14. Nuclear Localization Signal Enhances the Targeting and Therapeutic Efficacy of a Porphyrin-Based Molecular Cargo: A Systemic In Vitro and Ex Vivo Evaluation
    Naveen Kumar et al, 2024, Molecular Pharmaceutics CrossRef
15. A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
    Xiaochen Chen et al, 2021, Frontiers in Oncology CrossRef
16. Innovations in colorectal cancer treatment: trifluridine and tipiracil with bevacizumab for improved outcomes – a review
    Taruba Rais et al, 2024, Frontiers in Oncology CrossRef
17. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib
    Titto Augustine et al, 2019, Investigational New Drugs CrossRef